Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials.

Vaughn DW, Seifert H, Hepburn A, Dewe W, Li P, Drame M, Cohet C, Innis BL, Fries LF.

Hum Vaccin Immunother. 2014 Oct 3;10(10):2942-57. doi: 10.4161/21645515.2014.972149. Epub 2014 Nov 21.

PMID:
25483467
[PubMed - in process]
2.

Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial.

Langley JM, Frenette L, Jeanfreau R, Halperin SA, Kyle M, Chu L, McNeil S, Dramé M, Moris P, Fries L, Vaughn DW.

Vaccine. 2015 Jan 15;33(4):559-67. doi: 10.1016/j.vaccine.2014.11.018. Epub 2014 Nov 21.

PMID:
25448092
[PubMed - in process]
Free Article
3.

An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.

Raghunandan R, Lu H, Zhou B, Xabier MG, Massare MJ, Flyer DC, Fries LF, Smith GE, Glenn GM.

Vaccine. 2014 Nov 12;32(48):6485-92. doi: 10.1016/j.vaccine.2014.09.030. Epub 2014 Sep 28.

PMID:
25269094
[PubMed - in process]
Free Article
4.

Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial.

Nolan T, Roy-Ghanta S, Montellano M, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E, Kerdpanich A, Safadi MA, Cruz-Valdez A, Litao S, Lim FS, de Los Santos AM, Weber MA, Tinoco JC, Mezerville MH, Faingezicht I, Kosuwon P, Lopez P, Borja-Tabora C, Li P, Durviaux S, Fries L, Dubin G, Breuer T, Innis BL, Vaughn DW.

J Infect Dis. 2014 Aug 15;210(4):545-57. doi: 10.1093/infdis/jiu173. Epub 2014 Mar 20.

PMID:
24652494
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Gender Differences in Predictors of Self-Reported Physical Aggression: Exploring Theoretically Relevant Dimensions among Adolescents from Santiago, Chile.

Fries L, Grogan-Kaylor A, Bares C, Han Y, Delva J.

Int Perspect Psychol. 2013 Oct 1;2(4). doi: 10.1037/a0034533.

PMID:
24392266
[PubMed]
Free PMC Article
6.

A recombinant viruslike particle influenza A (H7N9) vaccine.

Fries LF, Smith GE, Glenn GM.

N Engl J Med. 2013 Dec 26;369(26):2564-6. doi: 10.1056/NEJMc1313186. Epub 2013 Nov 13. No abstract available.

PMID:
24224560
[PubMed - indexed for MEDLINE]
Free Article
7.

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM.

Vaccine. 2013 Sep 13;31(40):4305-13. doi: 10.1016/j.vaccine.2013.07.043. Epub 2013 Jul 26.

PMID:
23891795
[PubMed - indexed for MEDLINE]
Free Article
8.

Fishes of the Taquari-Antas river basin (Patos Lagoon basin), southern Brazil.

Becker FG, De Fries LC, Ferrer J, Bertaco VA, Luz-Agostinho KD, Silva JF, Cardoso AR, Lucena ZM, Lucena CA.

Braz J Biol. 2013 Feb;73(1):79-90.

PMID:
23644791
[PubMed - indexed for MEDLINE]
Free Article
9.

Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months.

Risi G, Frenette L, Langley JM, Li P, Riff D, Sheldon E, Vaughn DW, Fries L.

Vaccine. 2013 Jan 2;31(2):436-7. No abstract available.

PMID:
23387064
[PubMed - indexed for MEDLINE]
10.

The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call.

Tedder RS, Rodger AJ, Fries L, Ijaz S, Thursz M, Rosenberg W, Naoumov N, Banatvala J, Williams R, Dusheiko G, Chokshi S, Wong T, Rosenberg G, Moreea S, Bassendine M, Jacobs M, Mills PR, Mutimer D, Ryder SD, Bathgate A, Hussaini H, Dillon JF, Wright M, Bird G, Collier J, Anderson M, Johnson AM; Collaborative UK Study of Chronic Hepatitis B Infection (CUSHI-B) Study Group.

Clin Infect Dis. 2013 Apr;56(7):951-60. doi: 10.1093/cid/cis1013. Epub 2012 Dec 7.

PMID:
23223601
[PubMed - indexed for MEDLINE]
Free Article
11.

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine.

Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, Thomas DN, Hickman SP, Kpamegan E, Boddapati S, Piedra PA.

Vaccine. 2013 Jan 7;31(3):524-32. doi: 10.1016/j.vaccine.2012.11.009. Epub 2012 Nov 12.

PMID:
23153449
[PubMed - indexed for MEDLINE]
12.

Comparison of the Kato-Katz and Helmintex methods for the diagnosis of schistosomiasis in a low-intensity transmission focus in Bandeirantes, Paraná, southern Brazil.

Caldeira K, Teixeira CF, Silveira MB, Fries LC, Romanzini J, Bittencourt HR, Graeff-Teixeira C.

Mem Inst Oswaldo Cruz. 2012 Aug;107(5):690-2.

PMID:
22850963
[PubMed - indexed for MEDLINE]
Free Article
13.

Estimates of genetic parameters for visual scores and daily weight gain in Brangus animals.

Queiroz SA, Oliveira JA, Costa GZ, Fries LA.

Animal. 2011 May;5(6):838-43. doi: 10.1017/S1751731110002442.

PMID:
22440022
[PubMed]
14.

Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6-35 Months: A Randomized, Controlled Trial.

Langley JM, Vanderkooi OG, Garfield HA, Hebert J, Chandrasekaran V, Jain VK, Fries L.

J Pediatric Infect Dis Soc. 2012 Mar;1(1):55-63.

PMID:
23687572
[PubMed]
Free PMC Article
15.

A randomized, controlled trial in children to assess the immunogenicity and safety of a thimerosal-free trivalent seasonal influenza vaccine.

Domachowske JB, Blatter M, Chandrasekaran V, Liu A, Jain VK, Fries L.

Pediatr Infect Dis J. 2012 Jun;31(6):605-15. doi: 10.1097/INF.0b013e31824e2924.

PMID:
22333695
[PubMed - indexed for MEDLINE]
16.

Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant.

Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, Madariaga M, Fries L, Godeaux O, Vaughn D.

J Infect Dis. 2012 Mar 1;205(5):733-44. doi: 10.1093/infdis/jir641.

PMID:
22315336
[PubMed - indexed for MEDLINE]
Free Article
17.

Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study.

Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, Sheldon E, Collins H, Shepard M, Dionne M, Brune D, Ferguson L, Vaughn D, Li P, Fries L.

J Infect Dis. 2011 Jun 15;203(12):1729-38. doi: 10.1093/infdis/jir172.

PMID:
21606531
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months.

Risi G, Frenette L, Langley JM, Li P, Riff D, Sheldon E, Vaughn DW, Fries L.

Vaccine. 2011 Aug 26;29(37):6408-18. doi: 10.1016/j.vaccine.2011.04.072. Epub 2011 May 7. Erratum in: Vaccine. 2013 Jan 2;31(2):436-7. Dosage error in article text.

PMID:
21554915
[PubMed - indexed for MEDLINE]
19.

Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective.

Tavares F, Delaigle A, Slavin D, Bauchau V, Fries L, Seifert H.

Vaccine. 2011 Aug 26;29(37):6402-7. doi: 10.1016/j.vaccine.2011.04.026. Epub 2011 Apr 27.

PMID:
21527305
[PubMed - indexed for MEDLINE]
20.

Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.

Burt D, Mallett C, Plante M, Zimmermann J, Torossian K, Fries L.

Expert Rev Vaccines. 2011 Mar;10(3):365-75. doi: 10.1586/erv.10.172. Review.

PMID:
21434804
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk